Published in Medical Letter on the CDC and FDA, March 5th, 2006
This action marks the first time the agency has approved a new oncology product for two indications simultaneously.
Sutent, which received a priority review and was approved in less than 6 months, is a tyrosine kinase inhibitor working through multiple targets to deprive the tumor cells of the blood and nutrients needed to grow.
"Approval is a major step forward in making breakthrough treatments available...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA